SUPPLY CHAIN & SUSTAINABILITY
The COVID-19 pandemic served as a wake-up call to the industry ’ s supply chains , but what lessons should be learned and what is the roadmap forward ?
72
Perhaps one of the most notable revelations of the COVID-19 pandemic was the hard reality that supply chains were fragile , easily disrupted and difficult to adjust within the time-conscious environment they operate in . Providing adequate supplies of pharmaceuticals has taken on accelerated precedence in order to satisfy demand , not just domestically but also internationally to countries without the facilities to manufacture certain drugs in sufficient quantities . As other sectors adjust to operating in the ‘ new normal ’, pharmaceutical companies will be no different in examining ways that individuals , authorities and the industry as a whole can help to transform its supply chains for a new era .
Despite some room for optimism that current supply chains can simply be augmented to function in a new operational era , there are those who consider that the fundamental relationship between pharmaceutical companies , laboratories and the market needs to be redefined . PwC
SUMMER / AUTUMN 2020